The Association of PTEN Gene Mutations with the Breast Cancer Risk: A Systematic Review and Meta-analysis

Yari, Kheirollah; Hakimi, Ali; Mohammadi, Masoud; Ammari-Allahyari, Mojtaba; Salari, Nader; Ghasemi, Hooman

doi:10.1007/s10528-023-10464-z

Biochem Genet

2023

DOI: 10.1007/s10528-023-10464-z

|View full text |Cite|

The Association of PTEN Gene Mutations with the Breast Cancer Risk: A Systematic Review and Meta-analysis

Kheirollah Yari,

Ali Hakimi,

Masoud Mohammadi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Book1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Translational Genetics in Hereditary Cancers for Personalized Medicine Practice

Ajaz

2024

Personalized Medicine - New Perspectives [Working Title]

View full text Add to dashboard Cite

Elucidation of the molecular and cellular basis of disease has ushered in the era of personalized medicine. Current data indicate that 5–10% of cancers are hereditary, that is, caused by germline mutations in cancer predisposition genes. Examples include hereditary breast and ovarian cancers, von Hippel-Lindau syndrome, Cowden syndrome, and Lynch syndrome. The discoveries of causative genetic mutations have been possible due to the identification of families with a preponderance of cancers. After identifying patients with hereditary cancers through accurate family history, the next step is to identify the causative mutation(s) in these high-risk patients and individuals. Such detection can inform treatment; for instance, BRCA1/2 mutation carriers have now the option of intervention with Poly-ADP Ribose Polymerase (PARP) inhibitors such as olaparib and niraparib. It is important to emphasize that the study of hereditary forms of cancers has led to better treatment options not only for these cancers but also for the nonhereditary forms, which are more common. As next-generation sequencing becomes more affordable, it is likely that more causative mutations will be identified. This information can be translated for the development of either preventive or more suitable treatment strategies in cancers.

show abstract

Translational Genetics in Hereditary Cancers for Personalized Medicine Practice

Ajaz

2024

Personalized Medicine - New Perspectives [Working Title]

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Association of PTEN Gene Mutations with the Breast Cancer Risk: A Systematic Review and Meta-analysis

Cited by 1 publication

References 65 publications

Translational Genetics in Hereditary Cancers for Personalized Medicine Practice

Translational Genetics in Hereditary Cancers for Personalized Medicine Practice

Contact Info

Product

Resources

About